Market Dynamics

Substantial increase in number of patients suffering from viral infections and increasing R&D activities by major players for development of novel products are major factors expected to drive the growth of global antiviral drugs market. In US the proportion of outpatient visits for influenza-like illness increased slightly to 1.7 percent, which is below the national baseline of 2.2 percent. There is substantial increase in inpatients in hospitals for treatment of infections. According to U.S. Department of Health & Human Services, from October 2019, through April 4, 2020, there was 410,000-740,000 hospitalization related to flu and 24,000-62,000 deaths due to flu. According to World Health Organization, an estimated 491.5 million people were living with HSV-2 infection in 2016, equivalent to 13.2% of the world’s population aged 15 to 49 years. Increase in pandemic effect across the globe and rise in mortality rate are pressurizing the government to take necessary steps for drug development. Major players are focused on conducting rapid clinical trials for development of new drug, along with early product approval from the government as a preventive measure for treatment of covid-19 patients are factors cumulatively expected to augment the market growth. In 2020, the U.S. Food and Drug Administration granted full approval to the antiviral drug remdesivir as a treatment for patients hospitalized with COVID-19.

High investment by major players for new drug development and business development activities in order to enhance the business presence and increase the customer base is expected to boost the growth of antiviral drugs market.

In 2020, Glenmark Pharmaceuticals, a drug manufacturing company, launched its Favipiravir with brand name “FabiFlu” in the Indian market for treatment of covid-19. The company received approval from Drug Controller General of India (DCGI) for marketing and selling of the drug in the market.

In 2020, Cipla a global pharmaceutical company launched Favipiravir a Covid-19 drug for treatment of patients range especially in mild and moderate cases.

NeuroBo Pharmaceuticals, Inc. a clinical-stage biotechnology company acquired ANA Therapeutics, a privately held biotechnology company in 2021. The company is focused on developing ANA-001a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. This acquisition is expected to help the company to enhance the business and increase the customer base.

Factors such as high cost of R&D activities and stringent government regulations related to product approval are expected to hamper the growth of global antiviral drugs market. In addition, presence of generic drugs is expected to challenge the growth of target market. However, increasing investment by major players for cost effective drug development and supporting government regulations related to product approval and business establishment are factors expected to create new opportunities for players operating in the antiviral drugs market. In addition, increasing partnership and agreements between regional and international players is expected to support the revenue transaction of the target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global drugs market due to rise in number of patients suffering from chronic diseases. In addition, availability of advanced infrastructure in the country, increasing R&D activities, and focus on introduction of innovative drugs are factors expected to impact the growth of antiviral drugs market. Rise in business development activities through acquisitions and partnerships is expected to augment the regional market growth.

The market in Asia pacific is expected to witness faster growth in the antiviral drugs market due to increasing government spending on development of healthcare infrastructure. Favorable business policies by the government and focus on strengthening the regional manufacturing capabilities are factors expected to augment the regional market growth. In addition, government focus on development of hospital infrastructure in order to deliver enhanced care is expected to support the growth of antiviral drugs market.

Competitive Landscape                                                                                 

The global antiviral drugs market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Antiviral Drugs Market Segment Analysis, 2019

The global antiviral drugs market is segmented into type, drug class, and application. The drug class segment is bifurcated into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others. Among drug class, the reverse transcriptase inhibitors segment is expected to account for a major revenue share in the global antiviral drugs market. The application segment is divided into HIV, hepatitis, herpes, influenza, and others. Among applications, the HIV segment is expected to account for a noticeable revenue share in the global market. Players operating in the global antiviral drugs market are Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, and Dr. Reddy’s Laboratories Ltd.

Market Segmentation

Market By Drug Class

DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others

Market By Type

Branded
Generic

Market By Application

HIV
Hepatitis
Herpes
Influenza
Others

Market By Geography

North America
•    U.S.
•    Canada

Europe
•    U.K.
•    Germany
•    France
•    Spain
•    Rest of Europe

Asia-Pacific
•    China
•    Japan
•    India
•    Australia
•    South Korea
•    Rest of Asia-Pacific

Latin America
•    Brazil 
•    Mexico
•    Rest of Latin America

Middle East & Africa
•    GCC
•    South Africa
•    Rest of Middle East & Africa